Table 4. Reported cases of renal-associated AAV induced by COVID-19 vaccination.

ANCA: antineutrophil cytoplasmic antibody; AAV: ANCA-associated vasculitis; MPO: myeloperoxidase; PR3: proteinase 3.

Authors	Age/sex	COVID-19 vaccine type	Onset of symptoms	Clinical presentation	ANCA positivity	Management
Shakoor et al. [4]	79/F	Pfizer-BioNTech (second dose)	2 weeks	Weakness, upper thigh pain, acute kidney injury	MPO-ANCA	Steroids, cyclophosphamide
Dube et al. [6]	29/F	Pfizer-BioNTech (second dose)	16 days	Acute kidney injury	MPO-ANCA	Steroids, rituximab, cyclophosphamide
Takenaka et al. [7]	75/F	Pfizer-BioNTech (first dose)	4 days	Blurred vision	MPO-ANCA	Steroids
Sekar et al. [8]	52/M	Moderna (second dose)	2 weeks	Headache, weakness, acute kidney injury	PR3-ANCA	Steroids, cyclophosphamide
Anderegg et al. [9]	81/M	Moderna (second dose)	Not reported	Flu-like symptoms, acute kidney injury	PR3-ANCA	Steroids, cyclophosphamide, plasma exchange therapy
Al-Yafeai et al. [10]	62/F	Pfizer-BioNTech (first dose)	4 weeks	Weakness, hematemesis, arthralgia, acute kidney injury	PR3-ANCA	Steroids, cyclophosphamide, plasma exchange therapy